Pfizer Stock Jumps On $3.2 Billion U.S. Covid Vaccine Sale, FDA Paxlovid Approval Filing

Pfizer Stock Jumps On $3.2 Billion U.S. Covid Vaccine Sale, FDA Paxlovid Approval Filing
·2 min read

"As the Covid pandemic continues to evolve and be highly unpredictable, we must remain vigilant in protecting those who are at greatest risk of getting very sick from Covid," said CEO Albert Bourla.